SAN DIEGO --(BUSINESS WIRE)--Mar. 31, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022 . Management will hold a conference call to review the company's first quarter 2022 performance

SAN DIEGO --(BUSINESS WIRE)--Mar. 25, 2022-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one forward split (the “Stock Split”) of Dexcom’s common stock.

The best-selling real-time CGM in the world 1 is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app New system has the fastest sensor warmup on the market,* with no fingersticks † or scanning required Dexcom G7 builds on the trusted

Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring. 3 BURNABY, British Columbia --(BUSINESS WIRE)--Mar. 7, 2022-- Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time

Dexcom CGM to be evaluated for performance in the hospital and for the potential of more effective glycemic management and improved patient outcomes in the hospital setting Breakthrough Device Designation from the FDA is a critical milestone for in-patient Dexcom CGM use This designation provides a

SAN DIEGO --(BUSINESS WIRE)--Feb. 14, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences: Brice Bobzien , Vice President, Finance will present on behalf of the company at the SVB Leerink 11

SAN DIEGO --(BUSINESS WIRE)--Feb. 10, 2022-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2021 . Fourth Quarter 2021 Financial Highlights: Revenue grew 23% versus the same quarter of the prior year to $698.2 million on

Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly diabetes-related complications compared to fingerstick monitoring. 3 BURNABY, British Columbia --(BUSINESS WIRE)--Feb. 3, 2022-- Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose

SAN DIEGO --(BUSINESS WIRE)--Jan. 24, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Thursday, February 10, 2022 . Management will hold a conference call to review the company's fourth quarter

SAN DIEGO --(BUSINESS WIRE)--Jan. 10, 2022-- DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2021 to be approximately $698 million , an increase of 23%